Clinical Trial: A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07111832) titled 'A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer' on Aug. 01.

Brief Summary: This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

Intervention: DRUG: SHR-A1811 for Injection ...